Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Cancer Res. 2020 Jan 13;80(5):1171–1182. doi: 10.1158/0008-5472.CAN-19-2348

Figure 5: Clearance of senescent cells rescues chemotherapy-induced bone loss.

Figure 5:

(A) Experimental schematic for 1-week time point showing a single dose of Doxorubicin (Doxo; 10 mg/kg) and 3 doses of AP20187 (AP; 2 mg/kg) in 16-week old C57BL/6 INK-ATTAC mice. Dagger indicates time of sacrifice. (B) qRT-PCR analysis of p16, IL6, and HGMB1 from mRNA obtained from bone-resident cells present in tibias devoid of marrow from INK-ATTAC mice 7 days after dosing with Doxo and AP. N≥3 per group. qRT-PCR data are presented as mean±SD. (C) Experimental schematic for 4-week time point with dosing frequency of Doxo (5 mg/kg) and AP20187 (2mg/kg) and symbols as in A. (D) Trabecular (Tb) BV/TV of femurs and (E) cortical thickness of femurs. N≥6 per group. Data are presented as mean±SEM. *p<0.05, **p≤0.01, and ns=not significant.